Clinical Trial

PPIO-008 Tislelizumab Combined With S-1 in Patients With ypT+N0 ESCC After Radical Resection With Neoadjuvant STUDY

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
To explore the safety and efficacy of Tegafur combined with tislelizumab in patients with esophageal squamous cell carcinoma with residual primary lesion and node-negative after radical resection following neoadjuvant immunotherapy combined with chemotherapy
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-04-03; most recent amendment 2024-07-15.
Trial Details
NCT Number NCT06354140
Lead Sponsor Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Conditions Esophageal Squamous Cell Carcinoma
Enrollment 45 participants
Start Date 2024-05-07
Primary Completion 2027-05-30 (estimated)
Study Completion 2028-05-30 (estimated)
Updated on ClinicalTrials.gov 2024-07-17